Cabazitaxel
Information
- Drug Name
- Cabazitaxel
- Description
- Entry(CIViC)
- 1
CIViC
| Disease | Mutation | EL | ET | ED | CS | VO | TR | Pubmed | Links |
|---|---|---|---|---|---|---|---|---|---|
| prostate cancer | IGF2 OVEREXPRESSION IGF2 OVEREXPRESSION | D |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 3 | 25670080 | Detail |
Annotation
| Description | Associated Genes | Associated Variants | Sensitivity | Supported | Source | Links |
|---|---|---|---|---|---|---|
| OSI-906, an IGF1R/INSR inhibitor, sensitizes cell ... | IGF2 | IGF2 OVEREXPRESSION IGF2 OVEREXPRESSION | Sensitivity | true | CIViC Evidence | detail |
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04592237 | Active, not recruiting | Phase 2 | Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer | December 29, 2020 | December 31, 2025 |
| NCT03263650 | Active, not recruiting | Phase 2 | Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC | October 3, 2017 | June 30, 2024 |
| NCT03419234 | Active, not recruiting | Phase 2 | Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel | April 26, 2018 | April 1, 2026 |
| NCT02985957 | Active, not recruiting | Phase 2 | A Study of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650) | March 26, 2017 | January 7, 2025 |
| NCT02703623 | Active, not recruiting | Phase 2 | Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer | May 18, 2016 | March 31, 2026 |
| NCT02522715 | Active, not recruiting | Phase 1/Phase 2 | Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer | October 13, 2015 | July 1, 2024 |
| NCT02202772 | Active, not recruiting | Phase 1/Phase 2 | Intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the Treatment Urothelial Carcinoma of the Bladder | December 1, 2014 | April 2028 |
| NCT03934840 | Active, not recruiting | Phase 2 | CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone | October 10, 2019 | May 2025 |
| NCT01952223 | Active, not recruiting | Phase 3 | A Phase III of Cabazitaxel and Pelvic Radiotherapy in Localized Prostate Cancer and High-risk Features of Relapse | December 2013 | July 2041 |
| NCT01578655 | Completed | Phase 3 | Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer | August 2012 | July 2016 |
| NCT01594918 | Completed | Phase 1 | Phase I Cabazitaxel, Mitoxantrone, and Prednisone Metastatic Castration-Resistant Prostate Cancer | June 2012 | June 23, 2017 |
| NCT01600339 | Completed | Phase 2 | A Trial of Cabazitaxel for Advanced Transitional Cell Carcinoma (TCC) | May 2012 | January 2015 |
| NCT01620242 | Completed | Phase 2 | A Phase II, Open-Label, Multicenter Trial of Cabazitaxel in Patients With Recurrent or Metastatic Head and Neck Cancer After Failure Of Cisplatin, Cetuximab and Taxanes | April 2012 | May 27, 2014 |
| NCT01668459 | Completed | Phase 2/Phase 3 | Treatment of Locally Advanced or Metastatic Transitional Cell Carcinoma With Cabazitaxel | January 2013 | November 2017 |
| NCT01757171 | Completed | Phase 2 | Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma | December 2012 | June 2017 |
| NCT01693549 | Completed | Phase 2 | Study of Cabazitaxel in Patients With Metastatic Breast Cancer Previously Treated With Taxanes | September 2012 | July 20, 2017 |
| NCT01254279 | Completed | Phase 3 | Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen | December 2010 | December 2014 |
| NCT01420250 | Completed | Phase 1 | Cabazitaxel With Radiation and Hormone Therapy for Prostate Cancer | September 22, 2011 | July 21, 2020 |
| NCT01437488 | Completed | Phase 2 | Cabazitaxel in Patients With Urothelial Carcinoma Who Have Disease Progression Following Platinum-Based Chemotherapy | February 16, 2012 | March 30, 2017 |
| NCT01447225 | Completed | Phase 1 | Safety Study of MM-121 in Combination With Multiple Anticancer Therapies in Patients With Advanced Solid Tumors | October 2011 | January 2014 |
| NCT01500720 | Completed | Phase 2 | Cabazitaxel Compared to Topotecan for the Treatment of Small Cell Lung Cancer | March 2012 | April 2014 |
| NCT01505868 | Completed | Phase 1/Phase 2 | Cabazitaxel With or Without Carboplatin in Treating Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer | July 11, 2012 | December 9, 2019 |
| NCT01528163 | Completed | Phase 2 | Study Comparing Two Treatments in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | February 2012 | November 2014 |
| NCT01541007 | Completed | Phase 2 | A Study Looking at Novel Scheduling of Cabazitaxel for Patients With Metastatic Prostate Cancer | April 2012 | October 2015 |
| NCT01852578 | Completed | Phase 2 | Cabazitaxel in Relapsed and Metastatic NSCLC | September 2012 | August 2013 |
| NCT01866449 | Completed | Phase 2 | Prospective Phase 2 Trial of Cabazitaxel in Patients With Temozolomide Refractory Glioblastoma Multiforme | October 2013 | August 25, 2017 |
| NCT01913652 | Completed | Phase 2 | Ph II Cabazitaxel DD Liposarcoma | October 2014 | December 2020 |
| NCT01956149 | Completed | Phase 2 | Study With Cabazitaxel in Previously Treated Patients With Advanced or Metastatic Gastric Cancer | September 2013 | April 4, 2018 |
| NCT02512458 | Completed | Phase 2 | Study of the Effect of Chemotherapy With Cabazitaxel on Prostate Cancer | October 29, 2015 | December 27, 2019 |
| NCT02560337 | Completed | Phase 2 | Cabazitaxel in Patients With Recurrent Ovarian Cancer After Failure of Standard Therapy. | September 2015 | June 1, 2019 |
| NCT02903160 | Completed | Phase 2 | Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC) | January 13, 2017 | November 15, 2021 |
| NCT02961257 | Completed | Phase 3 | Trial Evaluating the Safety of 2 Schedules of Cabazitaxel in Elderly Men With mCRPC Previously Treated With a Docetaxel | May 5, 2017 | December 2, 2021 |
| NCT03101046 | Completed | Phase 2 | Treatment of Metastatic Castrate Resistant Prostate Cancer Patients According to Circulating Tumor Cells Kinetic | November 15, 2018 | December 31, 2021 |
| NCT03114254 | Completed | Phase 2 | A Trial of Cabazitaxel Chemotherapy in Relapsed Locally Advanced &/or Metastatic Carcinoma of the Penis | December 5, 2014 | November 16, 2016 |
| NCT03295565 | Completed | Phase 2/Phase 3 | Optimal Sequencing of Treatment Options for Poor Risk mCRPC Previously Treated With Docetaxel | May 7, 2017 | March 2, 2022 |
| NCT03392428 | Completed | Phase 2 | A Trial of 177Lu-PSMA617 Theranostic Versus Cabazitaxel in Progressive Metastatic Castration Resistant Prostate Cancer | January 29, 2018 | December 31, 2021 |
| NCT04495179 | Completed | Phase 2 | A Study of AZD4635 With Durvalumab and With Cabazitaxel and Durvalumab in Patients With mCRPC. | August 4, 2020 | August 8, 2022 |
| NCT05701007 | Completed | Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland | February 13, 2023 | April 10, 2024 | |
| NCT04622761 | Not yet recruiting | Phase 2 | Phase II Study of the Use of Neoadjuvant Cabazitaxel With Hormonal Treatment in Patients Operable Prostate Cancer, Assess the Efficacy and Toxicity of Cabazitaxel, and Explore Potential Predictive and Prognostic Markers of Clinical Outcome | January 15, 2021 | May 2, 2026 |
| NCT04709276 | Recruiting | Phase 2 | A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer | June 7, 2021 | June 2027 |
| NCT05818683 | Recruiting | Phase 1 | A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Castration-Resistant Prostate Cancer | April 26, 2023 | September 1, 2027 |
| NCT06353386 | Recruiting | Phase 1/Phase 2 | Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A) | May 20, 2024 | March 31, 2028 |
| NCT03048942 | Recruiting | Phase 2 | Pilot Study of Cabazitaxel and Paclitaxel in HER2 Negative Breast Cancer | November 2014 | August 2025 |
| NCT05563558 | Recruiting | Phase 2 | Pembrolizumab, Carboplatin and Cabazitaxel in Aggressive Metastatic Castration Resistant Prostate Cancer (PEAPOD_FOS) | May 5, 2023 | November 1, 2026 |
| NCT05340374 | Recruiting | Phase 1/Phase 2 | Cabazitaxel in Combination With 177Lu-PSMA-617 in Metastatic Castration-resistant Prostate Cancer | July 14, 2022 | December 2026 |
| NCT06085729 | Recruiting | Phase 1/Phase 2 | Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC) | February 29, 2024 | December 31, 2027 |
| NCT02204332 | Terminated | Phase 2 | Phase II-b Randomized Clinical Trial of Cabazitaxel in Metastatic Colorectal Cancer Resistant to Standard Treatment | March 2013 | |
| NCT02478502 | Terminated | Phase 2 | Testis CAB: Cabazitaxel as Salvage Treatment for Cisplatin-resistant Germ Cell Cancer | June 2015 | December 31, 2022 |
| NCT01747239 | Terminated | Phase 2 | Cabazitaxel in Platinum Refractory Ovarian Cancer | January 2013 | July 2014 |
| NCT01083615 | Terminated | Phase 3 | A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC) | March 2010 | March 2013 |
| NCT02844582 | Terminated | Phase 2 | Cabazitaxel and Prednisone in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | December 20, 2017 | June 4, 2019 |
| NCT01001221 | Terminated | Phase 1/Phase 2 | Dose-Escalation, Safety, Pharmacokinetics Study of Cabazitaxel With Gemcitabine In Patients With Solid Tumor | November 2009 | October 2011 |
| NCT03043989 | Terminated | Phase 1 | Cohorts of Docetaxel or Cabazitaxel in Combination With the Potent CYP3A4 Inhibitor, Clarithromycin | March 21, 2017 | July 26, 2019 |
| NCT01650285 | Terminated | Phase 2 | Cabazitaxel and Radiation For Patients With Prostate Cancer | January 2013 | July 2014 |
| NCT01845792 | Terminated | Phase 2 | Study of Abiraterone Acetate and Prednisone in Combination With Cabazitaxel in Patients With Prostate Cancer | July 2013 | February 2017 |
| NCT01531205 | Terminated | Phase 2 | Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSA | May 2012 | October 2013 |
| NCT03878524 | Terminated | Phase 1 | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | April 1, 2020 | December 10, 2020 |
| NCT01934894 | Terminated | Phase 2 | Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases | May 2014 | April 2017 |
| NCT01469338 | Terminated | Phase 2 | Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel | July 2012 | November 2014 |
| NCT02166658 | Terminated | Phase 2 | A Study of Cabazitaxel for Patients With Breast or Lung Cancer and Recurrent or Progressive Brain Metastases - Cabazitaxel for Brain Metastases (CaBaMet) | August 2015 | January 18, 2018 |
| NCT03257891 | Unknown status | Phase 2 | Cabazitaxel Activity in Patients With Advanced AdrenoCortical-Carcinoma Progressing After Previous Chemotherapy Lines | January 25, 2018 | January 24, 2022 |
| NCT02115165 | Unknown status | Phase 2 | A Prospective Study of Cabazitaxel in Patients With Non Seminomatous Germ-cell Tumors | May 2014 | May 2020 |
| NCT02254785 | Unknown status | Phase 2 | Cabazitaxel vs Abiraterone or Enzalutamide in Patients With Poor Prognosis Metastatic Castration-resistant Prostate Cancer | October 2014 | May 2020 |
| NCT03356912 | Unknown status | Phase 2 | CABAzitaxel With or Without Prednisone in Patients With Metastatic CAstration REsistant Prostate Cancer Progressed During or After a Previous Docetaxel-based Chemotherapy | November 22, 2017 | May 4, 2021 |
| NCT01830231 | Unknown status | Phase 2/Phase 3 | Cabazitaxel vs. Vinflunine in Metastatic or Locally Advanced Transitional Cell Carcinoma of the Urothelium (TCCU) | October 2012 | November 2016 |
| NCT03050866 | Unknown status | Phase 2 | Cabazitaxel in mCRPC Patients With AR-V7 Positive Circulating Tumor Cells (CTCs) | February 21, 2017 | August 19, 2022 |
| NCT02621190 | Withdrawn | Phase 2 | Cabazitaxel in mCRPC Patients With AR-V7 Positive CTCs | February 2016 | June 2019 |
| NCT01913067 | Withdrawn | Phase 2 | Evaluation of Cabazitaxel in Patients With Brain Metastasis Secondary to Breast Cancer and NSCLC | September 2013 | September 2016 |
| NCT01750866 | Withdrawn | Phase 2 | Cabazitaxel in Men 75 Years of Age or Older With Castration-Resistant Prostate Cancer | February 2013 | October 2013 |
| NCT01740570 | Withdrawn | Phase 1/Phase 2 | Phase I/II Cabazitaxel for Recurrent Malignant Glioma | April 2013 | |
| NCT01981668 | Withdrawn | Phase 1 | The JET Study: a Phase I Trial of Cabazitaxel, Radiotherapy and Long-term Androgen Deprivation | ||
| NCT02035124 | Withdrawn | Phase 2 | Cabazitaxel and BKM120 in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel | April 2014 | January 2015 |